Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 11

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 11
---
 III:        |
| Lon Cardon, Ph.D., FMedSci 
 William Fairey             
 Timothy Walbert            |     | Laurent Fischer, M.D.         
 Patrick Heron                 
 Saira Ramasastry, MS, M.Phil. |     | Laura Brege       
 Michael Grey      
 Christopher Peetz |

The Board currently has nine members. Upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “ Nominating Committee ”), the Board has considered and nominated the three incumbent directors listed below for election to the Board at the Annual Meeting to serve until the Company’s 2028 annual meeting of stockholders and until the director’s successor has been duly elected and qualified, or, if sooner, until the director’s earlier death, resignation or removal. All of the Company’s incumbent director nominees have previously been elected by our stockholders.

We have no reason to believe that any of the nominees will be unavailable or, if elected, will decline to serve. In the event that any of these nominees should become unavailable for election due to any presently unforeseen reason, proxies will be voted for a substitute as designated by the Board, or alternatively, the Board may leave a vacancy on the Board or reduce the size of the Board.

The biographies of each of the Board’s nominees for election to the Board as Class III directors, and all other directors, are set forth below, including the offices held, public company directorships and certain other business directorships, and the class and term of each director nominee and director. These biographies include information, as of the date of this Proxy Statement, regarding the specific and particular experience, qualifications, attributes or skills of each director or nominee that led the Nominating Committee to believe that that nominee should continue to serve on the Board. However, each of the members of the Nominating Committee may have a variety of reasons why he or she believes a particular person would be an appropriate nominee for the Board, and these views may differ from the views of other members. Nevertheless, we believe that, as a whole, our Board possesses the requisite skills and characteristics, leadership traits, work ethic and independence to provide effective oversight.

#### 10Mirum Pharmaceuticals2025 Proxy Statement

### TABLE OF CONTENTS

#### Proposal 1: Election of Directors
Class III Nominees for Election for a Three-year Term Expiring at the Company’s 2028 Annual Meeting of Stockholders

| Laura BregeIND